AFT Pharmaceuticals Limited (AFT) investor relations material

Opening remarks and agenda

• Meeting opened with formalities, introduction of directors, auditors, and senior management, and confirmation of quorum.

• Chair and Managing Director delivered opening addresses, followed by discussion, resolutions, general business, and meeting close.

• Agenda included presentations, formal business, resolutions, and opportunities for shareholder questions.

Financial performance review

• Achieved record results with 22% revenue growth to NZD 254.7 million and operating profit up 39% to NZD 24.4 million, exceeding guidance.

• Net profit after tax rose to NZD 14.1 million; products now sold in 87 countries.

• Group revenue and profit growth driven by strong performance in Australia (revenue up 19%), New Zealand (revenue up 11%), Asia (revenue up 41%), and international markets (revenue up 66%).

• Multi-year compound annual growth rate exceeds 17%, outperforming global peers.

• Net debt increased to NZD 38.6 million, within target range, due to inventory and new licenses; new banking facility of NZD 50 million secured to support growth.

Board and executive committee updates

• Marree Atkinson retired by rotation and offered herself for re-election, with board support.

• Malcolm Tubby, long-serving CFO, retired; Stuart Houliston appointed as new CFO.

• Chair David Flacks announced intention to retire within 12 months, assisting with transition.

• Board includes Managing Director/CEO, Executive Director/Chief of Staff, and three Independent Directors.